Dec 12, 2025
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving…
Dec 11, 2025
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing…
Nov 12, 2025
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
Jun 27, 2025
Med (Cell Press) 2025
Sep 19, 2024
Lancet Respiratory Medicine 2024
Sep 14, 2023
JNCCN 2023
Nov 16, 2025
PP01.45: Phase 3 Study of Plinabulin/Docetaxel vs. Docetaxel in 2L/3L…
Oct 23, 2025
Phase 2 study of pembrolizumab (Pemb) plus plinabulin (Plin) and…
Sep 10, 2025
Immune Activation with Plinabulin Enhances Anti-tumor Response Combining Radiation with…
Nov 10, 2024
11.2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (2024)…
Sep 23, 2024
09.2024 European Society for Medical Oncology (ESMO) Congress 2024 Plinabulin/Docetaxel…
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung…
Sep 16, 2024
Plinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio over Docetaxel Alone: Significant…
Median PFS at 8.63 months and Disease Control Rate of…
Sep 10, 2024
09.2024 International Association for the Study of Lung Cancer (IASLC)…
Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk…
Email us at
Call us at
Office location